Dexmedetomidine Versus Ketamine-midazolam Sedation in Awake Fiberoptic Intubation in Suspected Difficult Airway

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

January 20, 2024

Study Completion Date

April 4, 2024

Conditions
Awake Fiberoptic Intubation
Interventions
DRUG

Dexmedetomidine

In Dexmedetomidine group: patients received an intravenous dose of dexmedetomidine at 1 mcg/kg over 10 min in 100 mL normal saline followed by continous infusion of dexmedetomidine at 0.2mcg/kg/h up to 0.7mcg/kg/hr till reaching Ramsay sedation score 2-3

DRUG

Ketamine plus Midazolam

In Ketamine Midazolam group: patients received midazolam 0.02 mg /kg IV then 2 minutes later take ketamine 0.25 mg/kg IV and we will repeated this mixture till reaching Ramsay sedation score 2-3

Trial Locations (1)

44511

Faculty of Medicine Zagazig University, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT06946212 - Dexmedetomidine Versus Ketamine-midazolam Sedation in Awake Fiberoptic Intubation in Suspected Difficult Airway | Biotech Hunter | Biotech Hunter